Aqilion and Merck partner to develop TAK1 protein inhibitorsTAK1 protein inhibitors
2023-02-17
引进/卖出蛋白降解靶向嵌合体
Preview
来源: Pharmaceutical Technology
The partnership aims to develop TAK1 therapeutics to treat several autoimmune and inflammatory diseases, including neurological diseases. Credit: Josh Riemer / Unsplash.
Aqilion and Merck have entered an exclusive licence and strategic research partnership for the discovery, development and commercialisation of the transforming growth factor-β-activated kinase 1 (TAK1) protein-small molecule inhibitors.
It will aim to develop advanced TAK1 therapeutics for various inflammatory and autoimmune diseases, including neurological diseases.
Aqilion will handle the design and synthesis of the new small molecule TAK1 inhibitors.
Merck will be responsible for leading the preclinical pharmacology and biology trials.
“We are looking forward to working with Merck as this will speed up the process of bringing novel effective treatments to conditions with high unmet medical needs.”
The company develops new therapeutics to treat diseases that are caused by chronic inflammation and dysfunctional immune reactions, including autoimmune diseases.
Earlier this month, Merck reported $13.83bn worldwide sales, representing a 2% increase in the fourth quarter (Q4) of 2022 from $13.52bn in the previous year’s quarter.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。